A promising obesity and diabetes drug stumbles in Alzheimer’s trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?
Novo Nordisk’s Latest Clinical Result Is Sending the Stock Plunging. Here’s What Investors Need to Know.
view original post